



June 17, 2024

Eli Lilly Canada Inc.

P.O. Box 73, Exchange Tower
130 King Street West, Suite 900
Toronto, Ontario M5X 1B1
1.416.694.3221 | 1.800.268.4446
www.lilly.ca

Dear Healthcare Provider,

We hear you.

Whether through one-on-one discussions, or in advisory capacities, we've heard you and understand that Lilly did not meet the expectations set for the launch of Mounjaro® in Canada.

We are actively working to address your concerns and we commit to improving communication with you, so that you are aware of important updates regarding supply in a timely manner.

Today, we have some positive news to share regarding supply:

- Supply for Mounjaro 2.5 mg and 5 mg single-dose vials has improved significantly, allowing us to update the status of our drug shortage reports for those 2 doses to "resolved" as of June 17, 2024.
- The confirmed supply and subsequent allocations will support new patient starts. Should you have patients in your practice who would benefit from Mounjaro, reliable supply of these doses is now available.
- If your patient experiences challenges filling their prescription of the 2.5 mg and the 5 mg doses, please contact our Customer Response Centre for assistance at 1-888-545-5972.
- Higher doses (7.5 mg and up to 15 mg) remain on shortage and Lilly is working to confirm supply timelines. In keeping with our commitment to you, we'll share updates on this as soon as we can.

Thank you again for the opportunity to address the issues. Please do not hesitate to share concerns; we are grateful for your time to provide this important feedback.

Please reach out if you have any questions.

Sincerely,

Kenneth L. Custer, Ph.D., MBA
President and General Manager
Eli Lilly Canada Inc.